ZFGN Zafgen Inc.

3.36
+0.04  (1%)
Previous Close 3.32
Open 3.33
Price To book 0.93
Market Cap 92345988
Shares 27,483,925
Volume 106,981
Short Ratio 6.95
Av. Daily Volume 122,472

SEC filingsSee all SEC filings

  1. EFFECT - Notice of Effectiveness 171048143
  2. S-3 - Registration statement under Securities Act of 1933 171018339
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018308
  4. 8-K - Current report 171015079
  5. 8-K - Current report 17927640

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced September 12, 2017. Interim data due 1H 2018.
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity

SEC Filings

  1. EFFECT - Notice of Effectiveness 171048143
  2. S-3 - Registration statement under Securities Act of 1933 171018339
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018308
  4. 8-K - Current report 171015079
  5. 8-K - Current report 17927640
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826878
  7. 8-K - Current report 17826766
  8. 8-K - Current report 17814061
  9. DEF 14A - Other definitive proxy statements 17796004
  10. S-8 - Securities to be offered to employees in employee benefit plans 17682237